Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Peripheral neuropathies

Subcutaneous immunoglobulin — the future of CIDP treatment?

Nature Reviews Neurology volume 14, pages 130–131 (2018)Cite this article

Subjects

Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). This finding represents an important step in the management of patients with immunoglobulin-responsive CIDP, with considerable implications for the cost of treatment and, most importantly, for these patients' quality of life.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mathey, E. K. et al. Chronic inflammatory demyelinating polyneuropathy: from pathology to phenotype. J. Neurol. Neurosurg. Psychiatry 86, 973–985 (2015).

    Article  Google Scholar 

  2. van den Berg, B. et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 10, 469–482 (2014).

    Article  CAS  Google Scholar 

  3. Mathey, E. K. et al. Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. J. Neuroimmunol. 309, 41–46 (2017).

    Article  CAS  Google Scholar 

  4. Schmidt, B. et al. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19, 474–487 (1996).

    Article  CAS  Google Scholar 

  5. Oaklander, A. L. et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst. Rev. 1, CD010369 (2017).

    PubMed  Google Scholar 

  6. Racosta, J. M., Sposato, L. A. & Kimpinski, K. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis. Muscle Nerve. 55, 802–809 (2017).

    Article  CAS  Google Scholar 

  7. van Schaik, I. N. et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. https://doi.org/10.1016/S1474-4422(17)30378-22017 (2017).

  8. Berger, M., Rojavin, M. A., Kiessling, P. & Zenker, O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin. Immunol. 139, 133–141 (2011).

    Article  CAS  Google Scholar 

  9. Berger, M., Jolles, S., Orange, J. S. & Sleasman, J. W. Bioavailability of IgG administered by the subcutaneous route. J. Clin. Immunol. 33, 984–990 (2013).

    Article  CAS  Google Scholar 

  10. Wakerley, B. R. & Yuki, N. Monitoring intravenous immunoglobulin dosing regimens in chronic inflammatory demyelinating polyneuropathy: search for a biomarker. J. Neurol. Neurosurg. Psychiatry 84, 830 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Benjamin R. Wakerley is at the Department of Neurology, UK; and at the Nuffield Department of Clinical Neurosciences, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, University of Oxford, John Radcliffe Hospital, Headley Way, OX3 9DU, Oxford, UK.,

    Benjamin R. Wakerley

  2. and at the Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Headley Way, OX3 9DU, Oxford, UK.,

    Benjamin R. Wakerley

  3. Nobuhiro Yuki is at the Department of Medicine, Eda Memorial Hospital, Azamino-minami 1-1-1, Aoba-ku, Yokohama, Kanagawa, 225-0012, Japan.,

    Nobuhiro Yuki

Authors
  1. Benjamin R. Wakerley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobuhiro Yuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin R. Wakerley.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wakerley, B., Yuki, N. Subcutaneous immunoglobulin — the future of CIDP treatment?. Nat Rev Neurol 14, 130–131 (2018). https://doi.org/10.1038/nrneurol.2017.179

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.179

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing